Zeon Corporation has made a strategic $50 million investment in Chemify, a UK-based digital chemistry pioneer, through its venture arm Zeon Ventures. The move positions Zeon at the forefront of automated molecular design and synthesis, accelerating the creation of novel compounds for medicines and advanced materials.

 

“Through this investment and partnership, we aim to leverage Chemify’s cutting-edge technology to further accelerate our digital chemistry initiatives and drive the creation of new materials and compounds that can provide meaningful solutions to society’s most pressing challenges,” said Zeon Corporation.

 

Chemify’s breakthrough Chemputation technology digitizes and automates the entire chemical discovery process, converting target molecules into code that runs on robotic systems for fully automated Design–Make–Test–Analyze (DMTA) cycles. 

 

This approach allows access to unexplored chemical space and promises up to a 10-fold reduction in time from concept to synthesis. Last year, Chemify launched its first Chemifarm in Glasgow, one of the world’s most advanced automated chemistry labs, enabling rapid iteration from code to compound.

 

“The development of novel, makeable molecules is essential to helping address global challenges in human health, energy conservation, and environmental sustainability,” the companies said.

 

Zeon has long championed digital transformation in chemical research, and the partnership with Chemify aligns with its STAGE30 medium-term management plan, targeting a 48% sales ratio from four growth sectors—Mobility, Healthcare and Life Science, Telecommunications, and Green Transformation—by fiscal 2028. 

 

Zeon emphasizes that investing in innovative companies and developing transformative new materials will help build a sustainable planet and a safe and comfortable society.